The concept of continuous low-dose ("metronomic") antiangiogenic chemotherapy.

被引：0
|
作者：
Klement, G
Kerbel, R
机构：
[1] Sunnybrook & Womens Coll, Ctr Hlth Sci, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
048
引用
收藏
页码：4483S / 4483S
页数：1
相关论文
共 50 条
  • [31] LOW-DOSE METRONOMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND METHOTREXATE IN METASTATIC BREAST CANCER PATIENTS
    Krajnak, S.
    Battista, M.
    Elger, T.
    Stewen, K.
    Heimes, A. S.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 636 - 636
  • [32] Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy
    Chow, Annabelle
    Wong, Amy
    Francia, Giulio
    Man, Shan
    Kerbel, Robert S.
    Emmenegger, Urban
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 47 - 59
  • [33] Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice
    Jiang, Hongchi
    Tao, Weiyang
    Zhang, Mu
    Pan, Shangha
    Kanwar, Jagat R.
    Sun, Xueying
    CANCER INVESTIGATION, 2010, 28 (01) : 74 - 84
  • [34] Inhibition of Multidrug Transporter in Tumor Endothelial Cells Enhances Antiangiogenic Effects of Low-Dose Metronomic Paclitaxel
    Akiyama, Kosuke
    Maishi, Nako
    Ohga, Noritaka
    Hida, Yasuhiro
    Ohba, Yusuke
    Alam, Mohammad Towfik
    Kawamoto, Taisuke
    Ohmura, Hitomi
    Yamada, Kenji
    Torii, Chisaho
    Shindoh, Masanobu
    Hida, Kyoko
    AMERICAN JOURNAL OF PATHOLOGY, 2015, 185 (02): : 572 - 580
  • [35] Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel
    Moes, Johannes
    Koolen, Stijn
    Huitema, Alwin
    Schellens, Jan
    Beijnen, Jos
    Nuijen, Bastiaan
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 83 (01) : 87 - 94
  • [36] Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
    Munoz, R
    Shaked, Y
    Bertolini, F
    Emmenegger, U
    Man, S
    Kerbel, RS
    BREAST, 2005, 14 (06): : 466 - 479
  • [37] Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
    Loven, David
    Hasnis, Erez
    Bertolini, Francesco
    Shaked, Yuval
    DRUG DISCOVERY TODAY, 2013, 18 (3-4) : 193 - 201
  • [38] Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    Shaked, Y
    Emmenegger, U
    Man, S
    Cervi, D
    Bertolini, F
    Ben-David, Y
    Kerbel, RS
    BLOOD, 2005, 106 (09) : 3058 - 3061
  • [39] Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
    Kong, Doo-Sik
    Lee, Jung-Il
    Kim, Jong Hyun
    Kim, Sung Tae
    Kim, Won Seog
    Suh, Yeon-Lim
    Dong, Seung Myung
    Nam, Do-Hyun
    NEURO-ONCOLOGY, 2010, 12 (03) : 289 - 296
  • [40] PHASE II TRIAL OF LOW-DOSE CONTINUOUS (METRONOMIC) TREATMENT OF TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
    Nam, Do-Hyun
    Kong, Doo-Sik
    Lee, Jung-Il
    Park, Kwan
    Kim, Jong Hyun
    NEURO-ONCOLOGY, 2008, 10 (05) : 841 - 841
12345